Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

President Trump reportedly held a “fiery” call with Denmark’s Prime Minister Mette Frederiksen over the president’s insistence that U.S. control of Greenland is necessary for American ...

was $540 now $319 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025.

and choosing the optimal meals for weight loss can be challenging. A research team has developed a weight management program that helps individuals plan meals with the assistance of a web ...

Novo Nordisk A/S soared the most since August after an experimental shot delivered as much as 22% weight loss in an ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

As Alzheimer’s disease is the most common form of dementia — affecting an estimated 6.7 million Americans — it’s not surprising that people who experience memory loss may suspect AD.

One year later, they did just that. Notre Dame showed enough growth since a shocking loss in September to Northern Illinois to supports the team’s confidence that the national championship could ...